| Category | Incidence rate (95% CI) | p-value |
---|---|---|---|
All | Â | 0.018 (0.006â0.042) | Â |
Primary disease | Breast | 0.025 (0.007â0.064) | 0.3968 |
Other | 0.008 (0â0.046) | Â | |
Stage at diagnosis | Stage 1â2 | 0.013 (0â0.069) | 1 |
Stage 3â4 | 0.014 (0.002â0.051) | Â | |
Gender | Female | 0.027 (0.009â0.063) | 0.1713 |
Male | 0 (0â0.039) | Â | |
Age | <â65 | 0.023 (0.005â0.065) | 0.6716 |
>â=â65 | 0.014 (0.002â0.049) | Â | |
Metastatic site: liver | No | 0.03 (0.01â0.068) | 0.1601 |
Yes | 0 (0â0.034) | Â | |
Metastatic site: lung | No | 0.013 (0.002â0.045) | 0.6548 |
Yes | 0.025 (0.005â0.072) | Â | |
Metastatic site: lymph node | No | 0.023 (0.005â0.066) | 0.669 |
Yes | 0.014 (0.002â0.049) | Â | |
Metastatic site: femur | No | 0.021 (0.007â0.049) | 1 |
Yes | 0 (0â0.086) | Â | |
Number of denosumab doses | <â10 | 0 (0â0.027) | 0.0605 |
>â=â10 | 0.035 (0.012â0.081) | Â | |
Number of denosumab doses | <â25 | 0.005 (0â0.025) | 0.0057 |
>â=â25 | 0.074 (0.021â0.179) | Â | |
Prior zoledronic acid treatment | No | 0.006 (0â0.033) | 0.0151 |
Yes | 0.071 (0.02â0.173) | Â |